AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02112084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized DPM
Description: The intervention includes 7 LO phone sessions and 7 RO home visits provided by trained interventionists. The primary focus of the LO phone conversations will be on grief work issues, daily functioning, and emotional support. The calls will provide an opportunity to discuss how grief could be interfering with their daily functioning, dealing with grief-related feelings- emotions they are experiencing, the frustrations associated with taking on new responsibilities while still trying to meet their own needs, critical time periods like anniversaries and holidays, unfinished business, coping strategies, including using humor, and having realistic expectations about the bereavement process. The RO home visits will be based specifically on the bereaved partners' skill and knowledge needs.
Study NCT00413114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate (GX15-070MS)
Study NCT00711126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: 5mcg IV
Study NCT00711126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: 10mcg IV
Study NCT01152437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: Patients receive BIBW 2992 tablets once daily, and can reduce dose for adverse event management
Study NCT00711126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: 100mcg inhaled
Study NCT00711126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: 20mcg IV
Study NCT00711126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: 500mcg oral
Study NCT04030767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox Injectable Product
Description: Botulinum toxin produces partial chemical denervation of the muscle resulting in localized reduction in muscle activity
Study NCT04030767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox Injectable Product
Description: Botulinum toxin produces partial chemical denervation of the muscle resulting in localized reduction in muscle activity
Study NCT01562925 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red wine
Description: Red wine First dosage: 3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.5 ml per kg bodyweight (60-120 minutes before contrast medium exposure
Study NCT02426593 — intervention group
Intervention type: DEVICE
Intervention: IMED-4
Description: Non-invasive novel lung hydration status sensor.
Study NCT03364673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitness Tracker
Description: Fitness trackers (e.g. Fitbit) are accelerometers that are worn on the wrist and tracks users' heart rate continuously in addition to steps, distance, calories, and active minutes
Study NCT03364673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Incentive (Way to Health)
Description: The Way to Health platform is an automated information technology platform that integrates wireless devices, clinical trial randomization and enrollment processes, messaging (text, e-mail or voice), self-administered surveys, automatic transfers of financial incentives, and secure data capture for research purposes.
Study NCT01562925 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: White wine
Description: White wine First dosage: 3.3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.7 ml per kg bodyweight (60-120 minutes before contrast medium exposure
Study NCT01562925 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beer
Description: Beer First dosage: 7.8 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 3.9 ml per kg bodyweight (60-120 minutes before contrast medium exposure
Study NCT05089097 — intervention group
Intervention type: OTHER
Intervention: evaluation of delirium with CAM-ICU Score
Description: the CAM-ICU score is an evaluation tool to verify the presence or absence of delirium in a subject
Study NCT01234116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine/tenofovir disoproxil fumarate
Description: Each health care worker will receive one of the Treatment Arms for 28 days.
Study NCT02377726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alkoholhjälpen counselor support
Description: Users will have access to counselor support through secure comments at the end of every module they complete in the self help program.
Study NCT02377726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eChange Alkoholhjälpen
Description: An internet based intervention program (iCBT) consisting of 5 modules. Fully automated self-help
Study NCT02377726 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alkoholhjälpen
Description: A swedish, open access website that includes information on alcohol, on how to find treatment and an internet discussion forum
Study NCT03473522 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Transcranial direct current stimulation is a modulation technique of neuronal excitability which has very promising results in Parkinson's disease. In addition to the possibility of increasing the excitability of areas to tDCS, it can also facilitate the execution of the exercises by increasing the excitability of the primary motor cortex and changing the recruitment strategies of the motor units.
Study NCT01491308 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cells transfusion
Description: This transfusion policy holds to any time from the start of surgery until discharge. The physicians caring for the patient will be instructed to administer transfusion, one unit at a time, and to measure the patient's hemoglobin concentration after each unit is transfused. In both groups, no further units will be given if the goal hemoglobin was obtained (7.5 g per deciliter for the restrictive arm and 10.0 g per deciliter for the liberal one). All other management decisions are left to the discretion of the patients' physicians. Attending physicians can administer RBC transfusions outside the rules of the protocol (i.e more than 1 unit at a time, without determining pre-transfusion hemoglobin) if severe acute bleeding occurs or other forms of circulatory shock.
Study NCT00058214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perifosine
Description: Given orally
Study NCT00058214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01906359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Native palm olein (IV56)
Description: Test meal consists of a high fat muffin (containing 50 g native palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
Study NCT01906359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemically interesterified palm olein (IV56)
Description: Test meal consists of a high fat muffin (containing 50 g chemically interesterified palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
Study NCT01906359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High oleic sunflower oil
Description: Test meal consists of a high fat muffin (containing 50 g high oleic sunflower oil) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
Study NCT01731899 — intervention group
Intervention type: DRUG
Intervention: agomelatine
Description: Agomelatine 25 mg pills. Initial dose 25 mg at bedtime; can be increased up to 50 mg at bedtime; 12 weeks duration
Study NCT03050697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HARMONI® Modular Toric Intraocular Lens
Description: Two-component system consisting of a base and a separate toric optic
Study NCT03050697 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract extraction with intraocular lens (IOL) implantation
Description: Cataract removal via manual phacoemulsification, followed by HMTIOL implantation
Study NCT03473522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Transcranial direct current stimulation is a modulation technique of neuronal excitability which has very promising results in Parkinson's disease. In addition to the possibility of increasing the excitability of areas to tDCS, it can also facilitate the execution of the exercises by increasing the excitability of the primary motor cortex and changing the recruitment strategies of the motor units.
Study NCT03473522 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Exercise Therapy
Description: Therapeutic exercises will be based on the literature (O'Sullivan and Schmitz 2004, Klamroth et al 2016, Reynolds et al., 2016, Pérez et al 2016, Smania et al., 2010, Pastor et al., 1993, Traub et al., 1980, Schoneburg et al., 2013) Each session will be divided into warm-up exercises; balance and relaxation, with a duration of 50 minutes and a frequency of 3 times a week. Training progresses and intensifies every two weeks. The subjects will perform five repeated movements of each exercise, evolving according to the condition of each patient (according to the Hoehn and Yahr staging scale).
Study NCT03473522 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: Therapeutic exercises will be based on the literature (O'Sullivan and Schmitz 2004, Klamroth et al 2016, Reynolds et al., 2016, Pérez et al 2016, Smania et al., 2010, Pastor et al., 1993, Traub et al., 1980, Schoneburg et al., 2013) Each session will be divided into warm-up exercises; balance and relaxation, with a duration of 50 minutes and a frequency of 3 times a week. Training progresses and intensifies every two weeks. The subjects will perform five repeated movements of each exercise, evolving according to the condition of each patient (according to the Hoehn and Yahr staging scale).
Study NCT03797924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Receive ICBN with ropivacaine
Description: ICBN block will be performed using US guidance depositing 10 ml of 0.5% ropivacaine in the plane between pectoralis minor and serratus anterior over the 2nd and 3rd intercostal space.
Study NCT03797924 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No ICBN block
Description: The site of injection will be prepped with tinted chlorhexidine
Study NCT01930812 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NaF PET/CT Imaging
Description: Diagnostic imaging test that is considered investigational
Study NCT01930812 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 99mTc-medronate whole body bone scan with SPECT
Description: 99mTc-medronate whole body bone scan with SPECT imaging. Note, that this is a standard procedure in this patient population and thus is not considered investigational.
Study NCT03475628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be given at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications prior to Daratumumab infusion to mitigate potential IRRs and post- infusion medications after Daratumumab infusion for the prevention of delayed IRRs
Study NCT03418168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat (BAY85-3934)
Description: Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
Study NCT00396331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF plus plerixafor
Description: Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 7 aphereses or until ≥ 2\*10\^6 CD34+ cells/kg were collected.
Study NCT03051139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-component LTVV implementation strategy
Description: Multicomponent LTVV implementation strategy consisting of: 1) physician orientation, 2) physician audit and feedback, and 3) clinical decision support comprised of a) an ARDS screening tool using a natural language processing (NLP) algorithm, b) EHR-based tasks for clinicians to complete, and c) a clinician reminder system.
Study NCT01058551 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Loop Recorder Insertion
Description: Implantable Loop Recorder Insertion. The device will be explanted after reaching outcome (First AF detected) or at 36 months
Study NCT01045915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: naked DNA coding for protein AMEP
Description: 2 injections 1 week interval of 4 increasing doses of plasmid with electrotransfer
Study NCT03678779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive
Description: $5 grocery gift card
Study NCT01152437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Patients receive cetuximab intravenously, once a week, every week
Study NCT04570384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Citrulline
Description: L-Citrulline (Turnobi) for Injection. Patients will receive an initial bolus of 20 mg/kg (maximum 1500 mg), followed by study infusion of 9 mg/kg per hour (maximum 700mg) for up to 10 days.
Study NCT04570384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to placebo will receive equal volume bolus and study infusion of 5% dextrose water for a maximum of 10 days.
Study NCT02192957 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lifepak 20E Defibrillator, Licence No: 61944
Description: Intervention will be carried out using Health Canada approved devices for electrical cardioversion, following the steps pre-specified in the Ottawa AF Protocol.~Ottawa AF Cardioversion
Study NCT03249818 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HITT device
Description: Device scans the fovea of the eye to measure fixation. Patients will then be asked to track the fixation target across an area the size of a playing card, with the device tracking the participant's fixation throughout.
Study NCT01359124 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exercise Cycle
Description: Exercise regimen: three monitored exercise sessions per week for eight weeks using the upright exercise cycle.
Study NCT01359124 — intervention group
Intervention type: BEHAVIORAL
Intervention: Land-based Treadmill
Description: Exercise regimen: three monitored exercise sessions per week for eight weeks using the land-based treadmill.
Study NCT01359124 — intervention group
Intervention type: BEHAVIORAL
Intervention: Water-based Treadmill
Description: Exercise regimen: three monitored exercise sessions per week for eight weeks using the water-based treadmill.
Study NCT03518021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone, intranasal
Description: Active compound naloxone 14 mg/ml, (±10%). Nasal spray will be administered with one puff (100 microL ±10%) in one nostril (1.4 mg dose) using the Aptar Unitdose device.~The spray device should be inserted about 1 cm into a nostril, pointing towards the ipsilateral ear and the plunger pushed in a firm and gentle manner for the formulation to be sprayed into the nose. After the plunger is inserted the device is immediately removed from the nose and assisted ventilation continued.
Study NCT03518021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo, intranasal
Description: Same spray but without naloxone. Nasal spray will be administered with one puff (100 microL +/- 10%) in one nostril using the Aptar Unitdose device.~The spray device should be inserted about 1 cm into a nostril, pointing towards the ipsilateral ear and the plunger pushed in a firm and gentle manner for the formulation to be sprayed into the nose. After the plunger is inserted the device is immediately removed from the nose and assisted ventilation continued.
Study NCT03518021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone, intramuscular
Description: Intramuscular comparator Naloxone Hydrochloride 0.4 mg/ml will be administered as a 2 ml intramuscular (IM) injection in the deltoid muscle, total dose of 0,8 mg naloxone IM
Study NCT03518021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo, intramuscular
Description: Intramuscular Sodium Chloride Injection 9mg/ml, will be administered as a 2 ml intramuscular injection in the deltoid muscle
Study NCT03988621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ViCCY
Description: Virtual Caregiver Coach for You
Study NCT01404234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZLI
Description: AZLI 75 mg was administered 3 times daily via the investigational nebulizer.
Study NCT03895073 — intervention group
Intervention type: OTHER
Intervention: healthy volunteers
Description: the questionnaire has been assessed by both groups, healthy and heart failure
Study NCT01480778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNG+EE2
Description: Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
Study NCT01480778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nordette
Description: Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
Study NCT02217969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic alert to SLUScore increase
Description: Treat hypotension to minimize further progression of the SLUScore
Study NCT01074931 — intervention group
Intervention type: DRUG
Intervention: Lopinavir/ritonavir (Kaletra)
Description: Lopinavir/ritonavir(LPV/r) is an HIV protease inhibitor (PI) that is co-formulated with lopinavir and ritonavir. Lopinavir is an inhibitor of the HIV-1 and HIV-2 proteases. As co-formulated in LPV/r, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.~The assignment of the patient to a lopinavir/ritonavir - containing regimen is not decided in advance by this protocol but falls within current practice and the prescription of lopinavir/ritonavir is clearly separated from the decision to include the patient in this study.
Study NCT04466891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZW25 (Zanidatamab)
Description: Administered intravenously
Study NCT02735291 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-targeted CAR-T cells
Description: This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months..
Study NCT02301442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise + behaviour change intervention
Description: In addition to the same exercise intervention as the control group, this group will receive a behaviour change intervention. This will be delivered after each exercise session and will incorporate the elements: self-efficacy, outcome expectations, impediments and goal-setting. On the weeks when the participants do not attend group sessions, they will receive telephone calls from physiotherapists. This will consist of guided conversations that consider content delivered in previous sessions.
Study NCT02301442 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise + control education
Description: The control group will receive exercise and education components. The exercise intervention includes aerobic \& strengthening components and are in line with MS exercise guidelines (Latimer-Cheung et al 2013). The aerobic activity is walking, measured using pedometers \& exercise logs. The strengthening programme consists of 10 exercises targeting major muscle groups for the upper and lower extremities using elastic resistance band. Over the 10-week programme participants will attend 6 group exercise class, supplemented with telephone calls in the weeks without classes. After each group exercise class this group will receive an education session about the following: diet, vitamin D, sleep, temperature and hydration, and immunisations and vaccinations.
Study NCT01456715 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil vaccine, Immunogenicity, Booster dose.
Description: Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Gardasil given 42 months later.
Study NCT01456715 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix Vaccine, Immunogenicity, Booster Dose.
Description: Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Cervarix given 42 months later.
Study NCT03145649 — intervention group
Intervention type: OTHER
Intervention: Dietary therapy or insulin injection
Study NCT06290297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation VRRS
Description: Telerehabilitation programs delivered at home, aiming to improve cognitive, motor and/or speech-language skills, through VRRS - Khymeia or Niurion devices. Such technologies are equipped with a wide library of activities to be performed also with the use of peripheral sensors. A one-shot assessment is also proposed to children admitted to institutes adhering to the project in order to understand the feasibility of the use of such devices. Ad hoc feasibility questionnaire are administered at the end of the one shot session and after the home training to the main stakeholders (children, families, clinicians)